GC
CBIO

Globeflex Capital’s Crescent Biopharma CBIO Stock Holding History

Globeflex Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1
Closed – – 476
2016
Q1 		$0 Hold
1
– – ﹤0.01% 458
2015
Q4 		$0 Hold
1
– – ﹤0.01% 468
2015
Q3 		$0 Hold
1
– – ﹤0.01% 525
2015
Q2 		$1K Hold
1
– – ﹤0.01% 434
2015
Q1 		$1K Buy
+1
New +$776 ﹤0.01% 435

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Globeflex Capital's CBIO Position: Q2 2016 in Review

Globeflex Capital sold out of Crescent Biopharma (CBIO) in Q2 2016, closing a stake of 1 share.

Globeflex Capital first reported a position in CBIO in Q1 2015 and held it in 5 quarters. The position peaked at $1K in Q2 2015. 50 funds tracked by Wall St. Rank hold CBIO as of Q2 2016.

  • Globeflex Capital reported no remaining Crescent Biopharma position as of Q2 2016 after selling out during the quarter.
  • Globeflex Capital sold 1 Crescent Biopharma share in Q2 2016.
  • Globeflex Capital first reported a position in Crescent Biopharma in Q1 2015 and held it in 5 quarters.
  • Globeflex Capital's Crescent Biopharma position peaked at $1K in Q2 2015.
  • 50 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2016.

Based on Globeflex Capital's 13F filing for Q2 2016, filed 10 Aug 2016.